XELOX III. Capecitabine (Xeloda) in Combination With Oxaliplatin (Eloxatin) as First-Line Treatment of Patients With Advanced or Metastatic Colorectal Cancer. A Randomized Phase II Study

Trial Profile

XELOX III. Capecitabine (Xeloda) in Combination With Oxaliplatin (Eloxatin) as First-Line Treatment of Patients With Advanced or Metastatic Colorectal Cancer. A Randomized Phase II Study

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 17 Jan 2017

At a glance

  • Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Acronyms XELOX-III
  • Most Recent Events

    • 01 Jan 2010 Results published in Annals of Oncology.
    • 24 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top